Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease

被引:14
作者
Droogsma, Erika [1 ]
van Asselt, Dieneke [1 ]
Diekhuis, Marjolein [1 ]
Veeger, Nic [2 ,3 ]
van der Hooft, Cornelis [1 ]
De Deyn, Peter Paul [4 ,5 ,6 ,7 ,8 ]
机构
[1] Med Ctr Leeuwarden, Dept Geriatr Med, NL-8901 BR Leeuwarden, Netherlands
[2] Med Ctr Leeuwarden, Dept Epidemiol, NL-8901 BR Leeuwarden, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Alzheimer Res Ctr, Groningen, Netherlands
[6] Univ Antwerp, Inst Born Bunge, ZNA, Dept Neurol, B-2020 Antwerp, Belgium
[7] Univ Antwerp, Inst Born Bunge, ZNA, Memory Clin, B-2020 Antwerp, Belgium
[8] Univ Antwerp, Inst Born Bunge, Lab Neurochem & Behav, B-2020 Antwerp, Belgium
关键词
Alzheimer's disease; real-life" setting; cholinesterase inhibitors; treatment response; course of cognition; longitudinal study; MINI-MENTAL-STATE; RANDOMIZED CONTROLLED-TRIALS; ACETYLCHOLINESTERASE INHIBITORS; EXTERNAL VALIDITY; GLOBAL PREVALENCE; CLINICAL-PRACTICE; DOUBLE-BLIND; DEMENTIA; GUIDELINES; PREDICTORS;
D O I
10.1017/S1041610215000289
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Some guidelines recommend to discontinue treatment with cholinesterase inhibitors (ChEIs) in patients with Alzheimer's disease (AD) without an initial response to ChEI treatment. Evidence supporting this recommendation, however, is limited. This study aimed to investigate the relation between the initial cognitive response to ChEI treatment and the subsequent long-term course of cognition of AD patients. Methods: The Frisian Alzheimer's Disease Cohort study is a retrospective longitudinal study of 576 community-dwelling AD patients treated with ChEIs in a "real-life" setting at a large memory clinic. A repeated measures analysis using a marginal model (population based averaged model) was applied to investigate whether there is a difference in the subsequent long-term course of cognition (Mini-Mental State Examination (MMSE)) between initial non-responders and responders. Absence of an initial response was defined as a lower MMSE score after the first six months of treatment compared to baseline, a positive response as the same or a higher MMSE score. Results: At baseline, median age was 80 years and the median MMSE score 23. Non-responders showed a slower rate of cognitive decline in the three subsequent years than responders, with a mean annual MMSE decline of 0.9 points versus 1.2 points, respectively (p < 0.0001). Conclusions: Our results suggest that it is not appropriate to discontinue ChEI treatment solely based on the absence of an initial cognitive response.
引用
收藏
页码:1323 / 1333
页数:11
相关论文
共 50 条
  • [41] Dual use of bladder anticholinergics and cholinesterase inhibitors: Long-term functional and cognitive outcomes
    Sink, Kaycee M.
    Thomas, Joseph
    Xu, Huiping
    Craig, Bruce
    Kritchevsky, Steven
    Sands, Laura P.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2008, 56 (05) : 847 - 853
  • [42] Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease:: multicenter trial
    Pirttilä, T
    Wilcock, G
    Truyen, L
    Damaraju, CV
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (11) : 734 - 741
  • [43] Serum vitamin D in patients with mild cognitive impairment and Alzheimer's disease
    Ouma, Shinji
    Suenaga, Midori
    Hatip, Funda F. Bolukbasi
    Hatip-Al-Khatib, Izzettin
    Tsuboi, Yoshio
    Matsunaga, Yoichi
    BRAIN AND BEHAVIOR, 2018, 8 (03):
  • [44] Prescribing cholinesterase inhibitors in mild cognitive impairment-Observations from the Alzheimer's Disease Neuroimaging Initiative
    Stage, Eddie
    Svaldi, Diana
    Sokolow, Sophie
    Risacher, Shannon L.
    Marosi, Krisztina
    Rotter, Jerome I.
    Saykin, Andrew J.
    Apostolova, Liana G.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2021, 7 (01)
  • [45] Effects of a multidisciplinar cognitive rehabilitation program for patients with mild Alzheimer's disease
    Viola, Luciane F.
    Nunes, Paula V.
    Yassuda, Monica S.
    Aprahamian, Ivan
    Santos, Franklin S.
    Santos, Glenda D.
    Brum, Paula S.
    Borges, Sheila M.
    Oliveira, Alexandra M.
    Chaves, Gisele F. S.
    Ciasca, Eliane C.
    Ferreira, Rita C. R.
    de Paula, Vanessa J. R.
    Takeda, Oswaldo H.
    Mirandez, Roberta M.
    Watari, Ricky
    Falcao, Deusivania V. S.
    Cachioni, Meire
    Forlenza, Orestes V.
    CLINICS, 2011, 66 (08) : 1395 - 1400
  • [46] Electrocardiographic Effects of Cholinesterase Inhibitors in Patients with Alzheimer's Disease
    Colak, Ayse
    Oz, Didem
    NAMIK KEMAL MEDICAL JOURNAL, 2022, 10 (04): : 401 - 405
  • [47] The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia
    Lojkowska, W
    Ryglewicz, D
    Jedrzejczak, T
    Minc, S
    Jakubowska, T
    Jarosz, H
    Bochynska, A
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 216 (01) : 119 - 126
  • [48] Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry
    Gallucci, Maurizio
    Spagnolo, Pierpaolo
    Arico, Maria
    Grossi, Enzo
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 50 (04) : 969 - 979
  • [49] Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study
    Canevelli, Marco
    Adali, Nawal
    Kelaiditi, Eirini
    Cantet, Christelle
    Ousset, Pierre-Jean
    Cesari, Matteo
    PHYTOMEDICINE, 2014, 21 (06) : 888 - 892
  • [50] Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors
    Sayer, R
    Law, E
    Connelly, PJ
    Breen, KC
    CLINICAL BIOCHEMISTRY, 2004, 37 (02) : 98 - 104